Express Scripts (ESRX) 84.90 $ESRX
AbbVie Seeks Japanese Approval for HCV Cocktail Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 12:30PM CST
AbbVie (ABBV) filed a new drug application with the Japanese Ministry of Health, Labour and Welfare for its experimental, all-oral, ribavirin and interferon free hepatitis C virus treatment.
ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), ABBV: 58.05 (+1.00)
Rite Aid (RAD) Jumps 6.6% on TPG's EnvisionRx Buyout - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 10:40AM CST
Rite Aid (RAD) announced that it has penned a deal with EnvisionRx, to buy the latter for roughly $2 billion.
ESRX: 84.90 (+0.40), WBA: 78.73 (-1.23), CVS: 102.63 (-0.37), RAD: 8.34 (+0.25)
Express Scripts Holding Becomes #29 Most Shorted Nasdaq 100 Component, Replacing Texas Instruments
MarketNewsVideo.com - Wed Feb 11, 4:31PM CST
The most recent short interest data has been released by the NASDAQ for the 01/30/2015 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." ...
ESRX: 84.90 (+0.40)
Look for Shares of Express Scripts to Potentially Pullback after Yesterday's 3.10% Rise
Comtex SmarTrend(R) - Wed Feb 11, 3:52PM CST
Express Scripts (NASDAQ:ESRX) traded in a range yesterday that spanned from a low of $82.23 to a high of $84.88. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $83.13 on volume of 4.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ESRX: 84.90 (+0.40)
SmarTrend Watching for Potential Pullback in Shares of Express Scripts After 3.10% Gain
Comtex SmarTrend(R) - Wed Feb 11, 3:51PM CST
Express Scripts (NASDAQ:ESRX) traded in a range yesterday that spanned from a low of $82.23 to a high of $84.88. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $83.13 on volume of 4.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ESRX: 84.90 (+0.40)
Rite Aid spends $2B on push into pharmacy benefit management
By TOM MURPHY - AP - Wed Feb 11, 2:22PM CST
Rite Aid's $2 billion acquisition of a pharmacy benefits manager steers the drugstore chain toward a potentially lucrative focus for health care companies: Finding ways to tame customer costs.
ESRX: 84.90 (+0.40), WBA: 78.73 (-1.23), SWY: 35.10 (-0.04)
AstraZeneca to pay $7.9 million over kickback allegations
By RANDALL CHASE - AP - Wed Feb 11, 1:53PM CST
DOVER, Del. (AP) — Pharmaceutical manufacturer AstraZeneca LP will pay $7.9 million to settle allegations that it engaged in a kickback scheme involving the heartburn medicine Nexium, U.S. Justice Department officials said Wednesday.
ESRX: 84.90 (+0.40)
Achillion: Hep C Drug Discounting May Hurt Our Market Value, Stock Price
at The Street - Wed Feb 11, 8:04AM CST
Achillion Pharmaceuticals announced a 10 million-share stock offering Tuesday night.
ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), CVS: 102.63 (-0.37), ABBV: 58.05 (+1.00)
3 Blockbuster Drugs That May Be Obsolete in 5 Years
Motley Fool Staff - Motley Fool - Sat Feb 07, 12:28PM CST
Blockbuster status is the Holy Grail for drug developers, but patent expirations mean these billion-dollar drugs have a limited shelf life. These three drugs, for example, have been among the planet's best-sellers, but over the course of the next...
JNJ: 99.62 (+1.18), BIIB: 391.66 (-0.45), ESRX: 84.90 (+0.40), PTLA: 34.96 (+3.13), PFE: 34.64 (-0.23), AZN: 69.96 (+0.20), TEVA: 56.77 (-0.58), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56), MNTA: 11.70 (-0.06), NVS: 102.20 (-0.17)
5 Key Findings After 1 Full Year of Obamacare
Todd Campbell, The Motley Fool - Motley Fool - Sat Feb 07, 8:51AM CST
Source: The White House via Flickr. The Affordable Care Act enrolled millions of Americans in health insurance plans during its first open enrollment period, which began in October of 2013 and ended in March 2014, and the first real-time results of...
CI: 114.47 (-0.51), ANTM: 141.05 (-0.95), ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), TEVA: 56.77 (-0.58)
Can Gilead Boost HCV Sales with Health Service Deals? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 4:47PM CST
Gilead has entered into agreements with several pharmacy benefit managers and health care service companies for its HCV drugs.
CI: 114.47 (-0.51), ESRX: 84.90 (+0.40), ALNY: 95.54 (+1.67), GILD: 101.90 (+1.10), ABBV: 58.05 (+1.00)
McKesson Corporation Leads The 20 Best Value Bond Trades With Maturities Of 1 Year Or More
Donald van Deventer - at Seeking Alpha - Fri Feb 06, 1:29PM CST
BDX: 143.71 (+0.72), MCK: 224.89 (+0.12), LO: 67.30 (-0.80), AMGN: 153.48 (+0.30), AWH: 40.50 (-0.19), PEP: 99.13 (-1.14), MKL: 731.94 (+4.29), ESRX: 84.90 (+0.40), GS: 189.00 (-0.78), R: 93.92 (+0.41), DTV: 87.51 (-0.32), BRK.B: 148.34 (-1.45), CIT: 46.17 (-0.36), BRK.A: 222,555.00 (-1,905.00)
AbbVie Inc. Earnings: After a Strong Year, Eyes Shift to 2015
Todd Campbell, The Motley Fool - Motley Fool - Wed Feb 04, 9:46AM CST
Source: AbbVie. AbbVie has gotten a lot of attention recently thanks to the much-anticipated approval of its hepatitis C drug Viekira Pak, but Viekira Pak's December approval means it didn't have much time on the market to move the needle for...
ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), SHPG: 239.82 (+6.11), ABBV: 58.05 (+1.00)
5 Things AbbVie Inc.'s Management Wants You to Know
Keith Speights, The Motley Fool - Motley Fool - Wed Feb 04, 8:03AM CST
Source: AbbVie By most measures, AbbVie performed well in the fourth quarter of 2014. Earnings handily beat expectations. Revenue increased in line with consensus forecasts. And yet shares dropped over 4% on Friday after the company released...
BIIB: 391.66 (-0.45), ABT: 46.09 (+0.87), ESRX: 84.90 (+0.40), ABBV: 58.05 (+1.00)
My Well-Valued Growth Portfolio Beats The S&P 500 For January
Psycho Analyst - at Seeking Alpha - Wed Feb 04, 6:46AM CST
ODFL: 76.25 (+0.96), ESRX: 84.90 (+0.40), THO: 59.19 (-0.44), SWKS: 81.85 (-0.57), LGIH: 13.38 (-0.07), LKQ: 27.22 (+0.10), DG: 68.82 (+1.23), SNY: 49.42 (+0.82), MNKD: 7.00 (+0.02), PCLN: 1,103.37 (+11.42), LUV: 43.30 (-0.20)
How Regeneron Pharmaceuticals, Sanofi, And Amgen Will Weather The Inevitable Price Wars
Investing Healthcare - at Seeking Alpha - Tue Feb 03, 9:30PM CST
ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), AMGN: 153.48 (+0.30), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
What's Behind Gilead Sciences' Strong Q4 but Weak 2015 Outlook?
Keith Speights, The Motley Fool - Motley Fool - Tue Feb 03, 6:00PM CST
Source: Gilead Sciences. Investors anxiously awaiting Gilead Sciences ' fourth-quarter financial results can now take a deep breath. The biotech announced those results after the market close on Tuesday. Gilead's shares initially climbed...
ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), ABBV: 58.05 (+1.00)
4 Key Points To Look For In Gilead Sciences Earnings Report
Alexander J. Poulos - at Seeking Alpha - Tue Feb 03, 9:31AM CST
JNJ: 99.62 (+1.18), ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), ABBV: 58.05 (+1.00), NVS: 102.20 (-0.17), NASH: 31.48 (+0.01), FXR: 31.05 (+0.20)
Why Gilead Sciences, Inc. Shares Roared Higher By 11% in January
Sean Williams, The Motley Fool - Motley Fool - Mon Feb 02, 2:49PM CST
What: Shares of Gilead Sciences , a global pharmaceutical giant focused on developing therapies to fight a number of chronic diseases, roared higher by 11% in January per S&P Capital IQ following the announcement of two key agreements for...
ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), CVS: 102.63 (-0.37), ABBV: 58.05 (+1.00), AET: 96.12 (-0.96)
Will Gilead (GILD) Miss Q4 Earnings on Low HCV Drug Sales? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 2:30PM CST
Gilead Sciences, Inc. is set to report fourth-quarter 2014 results on Feb 3 after the market closes.
ACT: 285.37 (+3.71), ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), ABBV: 58.05 (+1.00), ACOR: 36.14 (-0.51)
AbbVie Seeks Japanese Approval for HCV Cocktail Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 12:30PM CST
AbbVie (ABBV) filed a new drug application with the Japanese Ministry of Health, Labour and Welfare for its experimental, all-oral, ribavirin and interferon free hepatitis C virus treatment.
ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), ABBV: 58.05 (+1.00)
Rite Aid (RAD) Jumps 6.6% on TPG's EnvisionRx Buyout - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 10:40AM CST
Rite Aid (RAD) announced that it has penned a deal with EnvisionRx, to buy the latter for roughly $2 billion.
ESRX: 84.90 (+0.40), WBA: 78.73 (-1.23), CVS: 102.63 (-0.37), RAD: 8.34 (+0.25)
Express Scripts Holding Becomes #29 Most Shorted Nasdaq 100 Component, Replacing Texas Instruments
MarketNewsVideo.com - Wed Feb 11, 4:31PM CST
The most recent short interest data has been released by the NASDAQ for the 01/30/2015 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." ...
ESRX: 84.90 (+0.40)
Look for Shares of Express Scripts to Potentially Pullback after Yesterday's 3.10% Rise
Comtex SmarTrend(R) - Wed Feb 11, 3:52PM CST
Express Scripts (NASDAQ:ESRX) traded in a range yesterday that spanned from a low of $82.23 to a high of $84.88. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $83.13 on volume of 4.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ESRX: 84.90 (+0.40)
SmarTrend Watching for Potential Pullback in Shares of Express Scripts After 3.10% Gain
Comtex SmarTrend(R) - Wed Feb 11, 3:51PM CST
Express Scripts (NASDAQ:ESRX) traded in a range yesterday that spanned from a low of $82.23 to a high of $84.88. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $83.13 on volume of 4.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ESRX: 84.90 (+0.40)
Rite Aid spends $2B on push into pharmacy benefit management
By TOM MURPHY - AP - Wed Feb 11, 2:22PM CST
Rite Aid's $2 billion acquisition of a pharmacy benefits manager steers the drugstore chain toward a potentially lucrative focus for health care companies: Finding ways to tame customer costs.
ESRX: 84.90 (+0.40), WBA: 78.73 (-1.23), SWY: 35.10 (-0.04)
AstraZeneca to pay $7.9 million over kickback allegations
By RANDALL CHASE - AP - Wed Feb 11, 1:53PM CST
DOVER, Del. (AP) — Pharmaceutical manufacturer AstraZeneca LP will pay $7.9 million to settle allegations that it engaged in a kickback scheme involving the heartburn medicine Nexium, U.S. Justice Department officials said Wednesday.
ESRX: 84.90 (+0.40)
Achillion: Hep C Drug Discounting May Hurt Our Market Value, Stock Price
at The Street - Wed Feb 11, 8:04AM CST
Achillion Pharmaceuticals announced a 10 million-share stock offering Tuesday night.
ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), CVS: 102.63 (-0.37), ABBV: 58.05 (+1.00)
3 Blockbuster Drugs That May Be Obsolete in 5 Years
Motley Fool Staff - Motley Fool - Sat Feb 07, 12:28PM CST
Blockbuster status is the Holy Grail for drug developers, but patent expirations mean these billion-dollar drugs have a limited shelf life. These three drugs, for example, have been among the planet's best-sellers, but over the course of the next...
JNJ: 99.62 (+1.18), BIIB: 391.66 (-0.45), ESRX: 84.90 (+0.40), PTLA: 34.96 (+3.13), PFE: 34.64 (-0.23), AZN: 69.96 (+0.20), TEVA: 56.77 (-0.58), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56), MNTA: 11.70 (-0.06), NVS: 102.20 (-0.17)
5 Key Findings After 1 Full Year of Obamacare
Todd Campbell, The Motley Fool - Motley Fool - Sat Feb 07, 8:51AM CST
Source: The White House via Flickr. The Affordable Care Act enrolled millions of Americans in health insurance plans during its first open enrollment period, which began in October of 2013 and ended in March 2014, and the first real-time results of...
CI: 114.47 (-0.51), ANTM: 141.05 (-0.95), ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), TEVA: 56.77 (-0.58)
Can Gilead Boost HCV Sales with Health Service Deals? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 4:47PM CST
Gilead has entered into agreements with several pharmacy benefit managers and health care service companies for its HCV drugs.
CI: 114.47 (-0.51), ESRX: 84.90 (+0.40), ALNY: 95.54 (+1.67), GILD: 101.90 (+1.10), ABBV: 58.05 (+1.00)
McKesson Corporation Leads The 20 Best Value Bond Trades With Maturities Of 1 Year Or More
Donald van Deventer - at Seeking Alpha - Fri Feb 06, 1:29PM CST
BDX: 143.71 (+0.72), MCK: 224.89 (+0.12), LO: 67.30 (-0.80), AMGN: 153.48 (+0.30), AWH: 40.50 (-0.19), PEP: 99.13 (-1.14), MKL: 731.94 (+4.29), ESRX: 84.90 (+0.40), GS: 189.00 (-0.78), R: 93.92 (+0.41), DTV: 87.51 (-0.32), BRK.B: 148.34 (-1.45), CIT: 46.17 (-0.36), BRK.A: 222,555.00 (-1,905.00)
AbbVie Inc. Earnings: After a Strong Year, Eyes Shift to 2015
Todd Campbell, The Motley Fool - Motley Fool - Wed Feb 04, 9:46AM CST
Source: AbbVie. AbbVie has gotten a lot of attention recently thanks to the much-anticipated approval of its hepatitis C drug Viekira Pak, but Viekira Pak's December approval means it didn't have much time on the market to move the needle for...
ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), SHPG: 239.82 (+6.11), ABBV: 58.05 (+1.00)
5 Things AbbVie Inc.'s Management Wants You to Know
Keith Speights, The Motley Fool - Motley Fool - Wed Feb 04, 8:03AM CST
Source: AbbVie By most measures, AbbVie performed well in the fourth quarter of 2014. Earnings handily beat expectations. Revenue increased in line with consensus forecasts. And yet shares dropped over 4% on Friday after the company released...
BIIB: 391.66 (-0.45), ABT: 46.09 (+0.87), ESRX: 84.90 (+0.40), ABBV: 58.05 (+1.00)
My Well-Valued Growth Portfolio Beats The S&P 500 For January
Psycho Analyst - at Seeking Alpha - Wed Feb 04, 6:46AM CST
ODFL: 76.25 (+0.96), ESRX: 84.90 (+0.40), THO: 59.19 (-0.44), SWKS: 81.85 (-0.57), LGIH: 13.38 (-0.07), LKQ: 27.22 (+0.10), DG: 68.82 (+1.23), SNY: 49.42 (+0.82), MNKD: 7.00 (+0.02), PCLN: 1,103.37 (+11.42), LUV: 43.30 (-0.20)
How Regeneron Pharmaceuticals, Sanofi, And Amgen Will Weather The Inevitable Price Wars
Investing Healthcare - at Seeking Alpha - Tue Feb 03, 9:30PM CST
ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), AMGN: 153.48 (+0.30), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
What's Behind Gilead Sciences' Strong Q4 but Weak 2015 Outlook?
Keith Speights, The Motley Fool - Motley Fool - Tue Feb 03, 6:00PM CST
Source: Gilead Sciences. Investors anxiously awaiting Gilead Sciences ' fourth-quarter financial results can now take a deep breath. The biotech announced those results after the market close on Tuesday. Gilead's shares initially climbed...
ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), ABBV: 58.05 (+1.00)
4 Key Points To Look For In Gilead Sciences Earnings Report
Alexander J. Poulos - at Seeking Alpha - Tue Feb 03, 9:31AM CST
JNJ: 99.62 (+1.18), ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), ABBV: 58.05 (+1.00), NVS: 102.20 (-0.17), NASH: 31.48 (+0.01), FXR: 31.05 (+0.20)
Why Gilead Sciences, Inc. Shares Roared Higher By 11% in January
Sean Williams, The Motley Fool - Motley Fool - Mon Feb 02, 2:49PM CST
What: Shares of Gilead Sciences , a global pharmaceutical giant focused on developing therapies to fight a number of chronic diseases, roared higher by 11% in January per S&P Capital IQ following the announcement of two key agreements for...
ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), CVS: 102.63 (-0.37), ABBV: 58.05 (+1.00), AET: 96.12 (-0.96)
Will Gilead (GILD) Miss Q4 Earnings on Low HCV Drug Sales? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 2:30PM CST
Gilead Sciences, Inc. is set to report fourth-quarter 2014 results on Feb 3 after the market closes.
ACT: 285.37 (+3.71), ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), ABBV: 58.05 (+1.00), ACOR: 36.14 (-0.51)
